A Nomogram Including Sarcopenia for Predicting Progression-Free Survival in Patients with Localized Papillary Renal Cell Carcinoma: A Retrospective Cohort Study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study developed a prognostic nomogram for localized papillary renal cell carcinoma (pRCC) patients. The nomogram incorporates sarcopenia, body composition, tumor diameter, and surgical technique to predict cancer progression, aiding survival prognostication.
Area Of Science
- Urology
- Oncology
- Radiology
Background
- Subclassification removal for papillary renal cell carcinoma (pRCC) impacts survival prognostication post-surgery.
- Sarcopenia is a known prognostic factor in renal cell carcinoma (RCC) patients.
- Body composition parameters require comprehensive investigation for localized pRCC survival prediction.
Purpose Of The Study
- To investigate the survival prediction of body composition parameters for localized pRCC.
- To develop a prognostic model for predicting progression-free survival in localized pRCC patients.
Main Methods
- Retrospective analysis of 105 localized pRCC patients.
- Measurement of skeletal muscle index (SMI), subcutaneous adipose tissue (SAT), and perirenal adipose tissue (PRAT) from preoperative CT scans.
- Development of a prognostic nomogram using Cox regression analysis and validated with C-index and ROC curves.
Main Results
- Sarcopenia was present in 74.29% of patients.
- Multivariate analysis identified sarcopenia, SAT, PRAT, tumor diameter, and surgical technique as independent risk factors for progression.
- The developed prognostic nomogram demonstrated good predictive performance with a C-index of 0.831.
Conclusions
- A prognostic nomogram integrating sarcopenia, SAT, PRAT, tumor diameter, and surgical technique can predict progression in localized pRCC.
- This nomogram aids in survival prognostication for localized pRCC patients.
- Further external validation is required for clinical implementation.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...